Avoid common mistakes on your manuscript.
Frontotemporal dementia (FTD) is a clinically heterogeneous disease, characterized by behavioural, language and movement symptoms. The underlying pathology is termed frontotemporal lobar degeneration (FTLD) and consists of distinct underlying pathologies including aggregation of transactive response DNA-binding protein 43 (TDP-43), tau and fused-in-sarcoma (FUS) [7]. Approximately half of the FTLD cases have underlying TDP-43 pathology (FTLD-TDP), which can either be caused by a genetic mutation, with the most frequent being a hexanucleotide repeat expansion in C9orf72 or a mutation in progranulin (PRGN) or have a sporadic cause with no family history of dementia [7]. Currently, no ante-mortem biomarkers are available to distinguish between the different pathological subtypes, leaving challenges for diagnosis and therapeutic interventions. There is a growing interest in the eye, and in particular the retina, as a potential imaging biomarker for neurodegenerative diseases. As an extension of the brain, the retina displays anatomical and functional similarities. The accessibility of the retina provides a ‘window’ into the brain and a potential for noninvasive imaging of pathological changes in patients with a neurodegenerative disease. Previous research in human studies showed amyloid β (Aβ), phosphorylated tau and α-synuclein deposits in Alzheimer’s disease (AD), progressive supranuclear palsy (PSP) and Parkinson’s disease (PD) post-mortem retinas [5, 10, 12]. Recently, increased signals for phosphorylated TDP-43 (pTDP-43) were observed in the retina of cases with amyotrophic lateral sclerosis (ALS) [9]. Earlier it was reported that in a donor with ALS carrying a C9orf72 mutation, dipeptide pathology was present in the retina in the absence of TDP-43 pathology [2].
There are limited data on retinal changes in FTLD. In donors with FTLD due to PRGN mutation, retinal changes have been observed and include thinning and formation of fluorescent lesions, which precede symptoms of FTD [13, 14]. In a PRGN mouse model, neurodegeneration and nuclear depletion of TDP-43 was reported without TDP-43 aggregation [14]. Here we investigated the mislocalization of TDP-43 and presence of pTDP-43 in FTLD-TDP retina.
Post-mortem retina tissue was obtained from 7 donors with FTLD-TDP, of which four had a C9orf72 repeat expansion, one PRGN mutation and two were genetically sporadic (Netherlands Brain Bank, Amsterdam, The Netherlands). Pathologically, donors presented with FTLD-TDP types A (PRGN), B (C9orf72), C (sporadic) and E (sporadic) [6]. We also included donors with FTLD–tau (n = 5), FTLD-FUS (n = 1), AD with limbic-predominant age-related TDP-43 depositions (LATE) (n = 2) and without (n = 1), donors with ALS due to TDP-43 (ALS-TDP (n = 2)) and neurologically healthy controls (n = 6). Retinal TDP-43 pathological burden in FTLD-TDP donors was scored into none, few, frequent and abundant inclusions. Details and pTDP-43 scores of the donors are listed in Supplementary File 1. Immunohistochemical stainings were performed for (pan)TDP-43, phosphorylated TDP-43 (pTDP-43), p62 (SQSTM1), and the dipeptide repeat proteins (polyGA and polyGP). Double-fluorescence with calbindin D28K and calretinin was performed to identify horizontal cells and amacrine cells, respectively (for detailed procedures see Supplementary File 1).
In C9orf72 and PRGN mutation carriers, as well as the sporadic FTLD-TDP donors, TDP-43 aggregates were observed in the outer plexiform layer of the retina. No colocalization was found with markers for horizontal or amacrine cells. No TDP-43 inclusions were observed in the retina of FTLD-tau, ALS, AD, and neurologically healthy control donors. Interestingly, all C9orf72 mutation carriers showed abundant presence of p62 and display aggregation of dipeptides linked to the hexanucleotide repeat expansion in the inner nuclear layer of the retina [8]. The FTLD-TDP donors with advanced cortical and subcortical pathology, also showed the most abundant TDP-43 pathology (Fig. 1). One sporadic donor presented with a fast disease progression and had inclusions characteristic for FTLD-TDP type E. Characteristic for FTLD-TDP type E are small granular TDP-43 inclusions that are both P62- and ubiquitin negative [6]. In the retina, only few TDP-43 granular inclusions were observed, which is in concordance with the TDP-43 pattern observed in the brain.
The ALS patients included in the current study did not carry the C9orf72 hexanucleotide repeat expansion and showed no retinal or cortical TDP-43/dipeptide pathology. Recently, an increased signal for pTDP-43 in the retina was reported in 6 ALS donors [9]. This contradicts with an earlier report and the results from 2 donors in the current study [2]. While there is increasing evidence for in vivo retinal damage using ophthalmologic examination and post-mortem signs of neurodegeneration in cases with ALS, additional studies are needed to address the presence of pTDP-43 in retina in the context of ALS [11]. We observed pTDP-43 aggregates in the retina of C9orf72 mutation carriers. This suggests that genetic factors play a role in the occurrence of TDP-43 aggregates. On the other hand, we also observed TDP-43 aggregation in sporadic FTLD-TDP cases. Interestingly, TDP-43 inclusions in the retinal internuclear layer have been reported in subjects with chronic traumatic encephalopathy (CTE) [3]. This supports that TDP-43 inclusions in the retina can occur independent from underlying mutations. The absence of pTDP-43 positive aggregates in AD with limbic TDP-43 depositions suggests that the occurrence of TDP-43 aggregates in the retina relates to the severity of TDP-43 pathology in the brain, since within these limbic cases the TDP-43 pathology remains localized. In addition, timing could play a role as TDP-43 aggregation is secondary to AD-related pathology and mostly occurs in a later stage in AD [1, 4]. Additional studies are needed to determine if retinal TDP-43 aggregates contribute to a progressive cortical pathology or if they should be regarded as a primary retinal pathology.
To summarize, we report that manifestations of pathological TDP-43 are present in the retina of donors with FTLD-TDP. In donors with C9orf72 mutations, dipeptide pathology is also present in the retina. In this study, we observed no TDP-43 inclusions in the retina of 2 ALS donors without cortical TDP-43 depositions or AD patients with limbic TDP-43 pathology, suggesting that retinal TDP-43 pathology reflects the cortical involvement of TDP-43 aggregation. These findings provide opportunities for retinal TDP-43 aggregation as a biomarker for FTLD-TDP, using non-invasive retinal imaging techniques with the purpose of diagnosing and monitoring progression of FTLD-TDP.
Data availability
Most data generated or analyzed during this study are included in this published manuscript and the supplementary material. Additional data are available from the corresponding author upon reasonable request.
References
Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M et al (2013) Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 74:20–38. https://doi.org/10.1002/ana.23937
Fawzi AA, Simonett JM, Purta P, Moss HE, Lowry JL, Deng HX et al (2014) Clinicopathologic report of ocular involvement in ALS patients with C9orf72 mutation. Amyotroph Lateral Scler Frontotemporal Degener 15:569–580. https://doi.org/10.3109/21678421.2014.951941
Goodwill VDC, Chea L, Sigurdson C, Alvarez V, McKee A, Lin J (2020) Chronic traumatic encephalopathy is associated with TDP-43 retinal pathology. https://iovs.arvojournals.org/article.aspx?articleid=2768896
Josephs KA, Murray ME, Tosakulwong N, Weigand SD, Serie AM, Perkerson RB et al (2019) Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. Acta Neuropathol 137:227–238. https://doi.org/10.1007/s00401-018-1951-7
Koronyo Y, Rentsendorj A, Mirzaei N, Regis GC, Sheyn J, Shi H et al (2023) Retinal pathological features and proteome signatures of Alzheimer’s disease. Acta Neuropathol 145:409–438. https://doi.org/10.1007/s00401-023-02548-2
Lee EB, Porta S, Michael Baer G, Xu Y, Suh E, Kwong LK et al (2017) Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol 134:65–78. https://doi.org/10.1007/s00401-017-1679-9
Mackenzie IR, Neumann M (2016) Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies. J Neurochem 138(Suppl 1):54–70. https://doi.org/10.1111/jnc.13588
Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E et al (2013) The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 339:1335–1338. https://doi.org/10.1126/science.1232927
Pediconi N, Gigante Y, Cama S, Pitea M, Mautone L, Ruocco G et al (2023) Retinal fingerprints of ALS in patients: Ganglion cell apoptosis and TDP-43/p62 misplacement. Front Aging Neurosci 15:1110520. https://doi.org/10.3389/fnagi.2023.1110520
Schon C, Hoffmann NA, Ochs SM, Burgold S, Filser S, Steinbach S et al (2012) Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice. PLoS ONE 7:e53547. https://doi.org/10.1371/journal.pone.0053547
Soldatov VO, Kukharsky MS, Belykh AE, Sobolev AM, Deykin AV (2021) Retinal damage in amyotrophic lateral sclerosis: underlying mechanisms. Eye Brain 13:131–146. https://doi.org/10.2147/EB.S299423
Veys L, Vandenabeele M, Ortuno-Lizaran I, Baekelandt V, Cuenca N, Moons L et al (2019) Retinal alpha-synuclein deposits in Parkinson’s disease patients and animal models. Acta Neuropathol 137:379–395. https://doi.org/10.1007/s00401-018-01956-z
Ward ME, Chen R, Huang HY, Ludwig C, Telpoukhovskaia M, Taubes A et al (2017) Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aah5642
Ward ME, Taubes A, Chen R, Miller BL, Sephton CF, Gelfand JM et al (2014) Early retinal neurodegeneration and impaired Ran-mediated nuclear import of TDP-43 in progranulin-deficient FTLD. J Exp Med 211:1937–1945. https://doi.org/10.1084/jem.20140214
Acknowledgements
We would like to acknowledge all donors and their caregivers. We thank Michiel Kooreman (Netherlands Brain Bank) for helping with clinical data retrieval and his assistance at the Netherlands Brain Bank in collecting brain sections. This project was partly funded by Alzheimer Nederland, AN-project WE.03-2021-14.
Author information
Authors and Affiliations
Contributions
AAD, AJR and JJMH contributed to the study conception and design of the study. Experiments were performed by THJM and PG-P. Data collection was performed by AAD and FH-dR. The first draft of the manuscript was written by AAD and JJMH. All authors commented on later versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
Anke A. Dijkstra, Tjado H. J. Morrema, Frederique Hart-de Ruijter, Priya Gami-Patel, Frank D. Verbraak, Jurre den Haan, and Annemieke J. Rozemuller report no competing interests; Prof. dr. J. F. de Boer has acquired grant support (for the institution; Department of Physics, VU) from the Dutch Research Council (NWO) and from industry (Thorlabs, ASML, Heidelberg Engineering). He has received royalties related to IP on OCT technologies and semiconductor metrology. He has acted as an expert witness for a UK-based law firm; Dr. F. Bouwman performs contract research for Optina Dx and Optos, she has been an invited speaker at Roche and has been invited for expert testimony at Biogen. All funding is paid to her institution; Dr. J. J. M. Hoozemans received grants from the Dutch Research Council (ZonMW) and, Alzheimer Netherlands, performed contract research or received grants from Merck, ONO Pharmaceuticals, Janssen Prevention Center, DiscovericBio, AxonNeurosciences, Roche, Genentech, Promis, Denali, First Biotherapeutics, and Ensol Biosciences. All payments were made to the institution. Dr. J. J. M. Hoozemans participates in the scientific advisory board of Alzheimer Netherlands and is editor-in-chief for Acta Neuropathologica Communications.
Ethical approval
Prior to death donors signed informed consent for brain and eye autopsy and use of brain and eye tissue as well as medical records for research activities. This study was approved by the medical ethical committee of the VUmc (reference# 2009/148).
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Dijkstra, A.A., Morrema, T.H.J., Hart de Ruyter, F.J. et al. TDP-43 pathology in the retina of patients with frontotemporal lobar degeneration. Acta Neuropathol 146, 767–770 (2023). https://doi.org/10.1007/s00401-023-02623-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00401-023-02623-8